Merck is in superior talks to amass Acceleron Pharma Inc., in keeping with folks accustomed to the matter, in a transfer that might bolster the pharmaceutical big’s rare-disease enterprise.
The deal for Acceleron, which has a market worth of round $11 billion, may very well be introduced this week, assuming talks don’t disintegrate, the folks stated.
